Better Health: Smart Health Commentary Better Health (TM): smart health commentary

Article Comments (1)

Can Pharmacogenomic Tests Help To Improve Public Health?

Adverse drug events are a serious public health problem. Consider the following facts:

  • an estimated 82% of American adults take at least one medication and 29% take five or more;
  • 700,000 emergency department visits and 120,000 hospitalizations are due to adverse drug events annually;
  • $3.5 billion is spent on extra medical costs of adverse drug events annually;
  • at least 40% of costs associated with adverse drug events occurring outside hospitals can be prevented.

How can genomics help? Pharmacogenomics is the study of genetic variation as a factor in drug response, affecting both safety and effectiveness. The intended applications of pharmacogenomics research include identifying responders and non-responders to medications, avoiding adverse events, optimizing drug dose and avoiding unnecessary healthcare costs.  The Food and Drug Administration has added pharmacogenomic information to the labeling for more than 70 drugs. Labels may include information on genetic determinants of clinical response or risk for adverse events.

In spite of current enthusiasm about pharmacogenomics in the research community, very few pharmacogenomic tests have been evaluated for use in clinical practice at this time. Although considerable information is accumulating on the relationship between genetic variation and drug metabolism and adverse effects, precious little evidence exists for their added value in clinical practice.

One pharmacogenomic test that is recommended for use is a test for HLA-B*5701 to identify people at risk for an adverse effect of HIV treatment with abacavir. An open access journal, PLoS Currents Evidence on Genomic Tests, recently summarized evidence supporting the use of this test, excerpted here:

“There are approximately 33 million people worldwide who are living with HIV/AIDS. Among them are approximately 1.2 million Americans, with an estimated 56,300 newly diagnosed infections each year. Combination antiretroviral therapy is the most effective pharmacotherapy for HIV treatment. One of these drugs is abacavir. Abacavir hypersensitivity reaction affects 5 to 8% of patients and can be observed during the first 6 weeks of antiretroviral therapy.  Symptoms of an abacavir hypersensitivity reaction include skin rash, fever, malaise, gastrointestinal symptoms, and respiratory symptoms.  Rarely more severe forms of disease can occur.  If a patient experiences a hypersensitivity reaction, abacavir is discontinued and symptoms generally resolve within 72 hours. Restarting abacavir is contraindicated as it can result in a potentially life-threatening reaction and even death.  The HLA-B*5701 pharmacogenomic test minimizes potential toxicities to abacavir by identifying patients who may be at risk of developing a hypersensitivity reaction. Testing for HLA-B*5701 prior to initiation of abacavir has been recommended by the U.S. Department of Health and Human Services  (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents”.

Many other pharmacogenomic tests that are subjects of active research and debate–such as pharmacogenomic testing to guide warfarin dosing–have the potential for public health impact. For most of these tests, however, there is simply not enough evidence to warrant their use in practice at this time.

Public health has an important role in providing unbiased information to pharmacists, practitioners and policy makers about the value of these tests. One such effort funded by the CDC Office of Public Health Genomics is the pharmacogenomics education program conducted by the University of California at San Diego. The program seeks to provide continuing education courses and materials for pharmacists and health care providers to apply pharmacogenomic principles in practice.

Another crucial public health function is to continuously collect information, through surveys and surveillance systems on patterns of use of pharmacogenomic tests in practice to evaluate how these tests are affecting the health of the population.

The promise of pharmacogenomic tests for improving public health is great in the long run. But we should not take shortcuts in using them prematurely without the necessary scientific evidence that shows their added value in terms of improved health outcomes and reduced healthcare costs.

I am sure we will be writing about this topic again and again…

*This blog post was originally published at Genomics and Health Impact Blog*

You may also like these posts

    None Found

Read comments »

One Response to “Can Pharmacogenomic Tests Help To Improve Public Health?”

  1. Dr. Val says:

    I appreciate your very level-headed approach to the topic, Dr. Khoury. Consumer enthusiasm for DNA testing of all sorts (not just pharmacogenomics) has far outstripped the science at this point. Although I too am excited about the promise of personalized medicine, what we have now (in DTC DNA testing) often amounts to fortune-telling with a veneer of pseudoscience. The human body is so incredibly complex that 1:1 correlations are hard to come by, and our behavior affects our health to a large degree. We all want “Star Trek” medicine – but what many of us need to focus on is simply diet and exercise! 😉

Return to article »

Latest Interviews

IDEA Labs: Medical Students Take The Lead In Healthcare Innovation

It’s no secret that doctors are disappointed with the way that the U.S. healthcare system is evolving. Most feel helpless about improving their work conditions or solving technical problems in patient care. Fortunately one young medical student was undeterred by the mountain of disappointment carried by his senior clinician mentors…

Read more »

How To Be A Successful Patient: Young Doctors Offer Some Advice

I am proud to be a part of the American Resident Project an initiative that promotes the writing of medical students residents and new physicians as they explore ideas for transforming American health care delivery. I recently had the opportunity to interview three of the writing fellows about how to…

Read more »

See all interviews »

Latest Cartoon

See all cartoons »

Latest Book Reviews

Book Review: Is Empathy Learned By Faking It Till It’s Real?

I m often asked to do book reviews on my blog and I rarely agree to them. This is because it takes me a long time to read a book and then if I don t enjoy it I figure the author would rather me remain silent than publish my…

Read more »

The Spirit Of The Place: Samuel Shem’s New Book May Depress You

When I was in medical school I read Samuel Shem s House Of God as a right of passage. At the time I found it to be a cynical yet eerily accurate portrayal of the underbelly of academic medicine. I gained comfort from its gallows humor and it made me…

Read more »

Eat To Save Your Life: Another Half-True Diet Book

I am hesitant to review diet books because they are so often a tangled mess of fact and fiction. Teasing out their truth from falsehood is about as exhausting as delousing a long-haired elementary school student. However after being approached by the authors’ PR agency with the promise of a…

Read more »

See all book reviews »

Commented - Most Popular Articles